RVMD Stock - Revolution Medicines, Inc.
Unlock GoAI Insights for RVMD
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $11.58M | $35.38M | $29.39M | $42.98M |
| Gross Profit | N/A | $11.58M | $35.38M | $29.39M | $42.98M |
| Gross Margin | N/A | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-689,524,000 | $-487,185,000 | $-258,279,000 | $-188,008,000 | $-110,697,000 |
| Net Income | $-600,093,000 | $-436,367,000 | $-248,705,000 | $-187,091,000 | $-108,159,000 |
| Net Margin | N/A | -3768.3% | -703.0% | -636.6% | -251.6% |
| EPS | $-3.58 | $-3.86 | $-3.08 | $-2.47 | $-1.62 |
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Visit WebsiteEarnings History & Surprises
RVMDEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $-1.56 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-1.42 | $-1.61 | -13.4% | ✗ MISS |
Q3 2025 | Aug 6, 2025 | $-0.94 | $-1.31 | -39.4% | ✗ MISS |
Q2 2025 | May 7, 2025 | $-1.12 | $-1.13 | -0.9% | ✗ MISS |
Q1 2025 | Feb 26, 2025 | $-1.01 | $-1.12 | -10.9% | ✗ MISS |
Q4 2024 | Nov 6, 2024 | $-0.89 | $-0.94 | -5.2% | ✗ MISS |
Q3 2024 | Aug 7, 2024 | $-0.77 | $-0.81 | -5.2% | ✗ MISS |
Q2 2024 | May 8, 2024 | $-0.75 | $-0.70 | +6.2% | ✓ BEAT |
Q1 2024 | Feb 26, 2024 | $-0.86 | $-1.14 | -32.6% | ✗ MISS |
Q4 2023 | Nov 6, 2023 | $-1.01 | $-0.99 | +2.0% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.83 | $-0.92 | -10.8% | ✗ MISS |
Q2 2023 | May 8, 2023 | $-0.84 | $-0.72 | +14.3% | ✓ BEAT |
Q1 2023 | Feb 27, 2023 | $-0.84 | $-0.63 | +25.0% | ✓ BEAT |
Q4 2022 | Nov 7, 2022 | $-0.87 | $-0.87 | 0.0% | = MET |
Q3 2022 | Aug 9, 2022 | $-0.87 | $-0.82 | +5.7% | ✓ BEAT |
Q2 2022 | May 9, 2022 | $-0.82 | $-0.78 | +4.9% | ✓ BEAT |
Q1 2022 | Feb 28, 2022 | $-0.65 | $-0.71 | -9.2% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.62 | $-0.72 | -16.1% | ✗ MISS |
Q3 2021 | Aug 11, 2021 | $-0.55 | $-0.60 | -9.1% | ✗ MISS |
Latest News
Frequently Asked Questions about RVMD
What is RVMD's current stock price?
What is the analyst price target for RVMD?
What sector is Revolution Medicines, Inc. in?
What is RVMD's market cap?
Does RVMD pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to RVMD for comparison